Another biotech squeaked through the initial public offering (IPO) door Wednesday, as Xenon Pharmaceuticals Inc. priced 4 million shares at $9 to raise a smallish $36 million. But the IPO queue remained at three dozen companies after Inotek Pharmaceuticals Corp. entered as fast as Xenon could exit. The Lexington, Mass.-based biotech, which is developing a small molecule eye drop therapy to treat glaucoma, is seeking to raise up to $86 million, including overallotments, and plans to offer another $46 million in five-year convertible debt concurrent with the IPO.